{"id":3741,"date":"2018-03-26T20:04:42","date_gmt":"2018-03-26T20:04:42","guid":{"rendered":"https:\/\/terra-alliance.com\/staging\/?p=3741"},"modified":"2026-05-20T08:58:48","modified_gmt":"2026-05-20T08:58:48","slug":"exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare","status":"publish","type":"post","link":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/","title":{"rendered":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare"},"content":{"rendered":"<p>Paris, March 26, 2018: Ardian, a world-leading private investment house, and the Management and<br \/>\nShareholders of Groupe Bio7, announced today that they have signed an exclusive agreement for the<br \/>\nsale of Groupe Bio7, a French-based specialist in clinical analysis, to Cerba HealthCare, a European<br \/>\nleader in clinical pathology.<\/p>\n<p>Headed by Fr\u00e9d\u00e9ric Barroux, biologist, shareholder and founder, Groupe Bio7 is one of the leading<br \/>\nmulti-location clinical pathology groups in France. With 70 laboratories, the Group has a very strong<br \/>\npresence in the \u00cele-de-France region. Since 2016, Bio7 has extended its presence across the rest of<br \/>\nFrance, notably in the Indre-et-Loire and Oise regions.<\/p>\n<p>Groupe Bio7 is expected to generate pro forma revenue in excess of 110 million euros in 2018.<\/p>\n<p>Fr\u00e9d\u00e9ric Barroux, Chairman of Groupe Bio7, said: \u201cWe\u2019re thrilled and very proud to enable Groupe<br \/>\nBio7 to continue to expand and develop. The relationship between Bio7 and Cerba HealthCare, a<br \/>\nEuropean leader in clinical pathology, will help our Group to broaden its range of skills and services,<br \/>\nwhile continuing to apply a community-based approach designed to offer the best treatment plans for<br \/>\npatients.\u201d<\/p>\n<p>\u201cWe deeply thank Ardian for their support and involvement in our strategic planning, their support<br \/>\nand encouragement of our ongoing external growth, as well as the financial expertise of their teams,<br \/>\nespecially with regards to financing. The active involvement of Ardian within our Group has been a<br \/>\nsignificant factor in enabling the business to double in size since 2014.\u201d<\/p>\n<p>Fran\u00e7ois Jerphagnon, Head of the Ardian Expansion team, added: \u201cGroupe Bio7\u2019s sustained growth is<br \/>\ntestament to the long-term success of the collective and entrepreneurial project undertaken by the<br \/>\nGroupe Bio7 teams. As an investor and shareholder, we\u2019re especially pleased with the Group\u2019s<br \/>\ngrowth, driven both by a strong organic development of its sites, and the quality of acquisitions of<br \/>\nvarious sizes identified, carried out and harmoniously integrated within the Group. The partnership<br \/>\nwith Cerba HealthCare a leading international player in clinical pathology, will ensure that this success<br \/>\nis not only continued, but intensified.\u201d<\/p>\n<p>Catherine Courboillet, CEO of Cerba HealthCare, added: \u201cWe\u2019re excited to welcome Bio7 to Cerba<br \/>\nHealthCare. Under the impetus of Fr\u00e9d\u00e9ric Barroux, the group\u2019s biologists have built a solid and<br \/>\nprofessional laboratory network. We share their values of quality, respect and innovation, as well as<br \/>\nthe same vision of the future of medical biology. Together, we\u2019ll continue to build a model of<br \/>\nproximity biology and expertise that places the patient at the heart of healthcare.\u201d<\/p>\n<p>LIST OF PARTIES INVOLVED<\/p>\n<p style=\"padding-left: 40px;\">Cerba HealthCare (Catherine Courboillet, Cyril Dubreuil, J\u00e9r\u00f4me Thill)<br \/>\nGroupe Bio7 (Fr\u00e9d\u00e9ric Barroux, Florence Pajot, St\u00e9phane Konkuyt)<br \/>\nArdian Expansion (Fran\u00e7ois Jerphagnon, Marie Arnaud-Battandier, Arthur de Salins)<br \/>\nPartners Group (Christoph Rubeli, Kim Nguyen, Remy Hauser, Christopher Mauss)<br \/>\nPSP Investments (Simon Marc, Patrick Daignault, Philippe Bouchard, Mia Morisset)<\/p>\n<p style=\"padding-left: 40px;\">Advisors:<br \/>\nLegal advisor to Cerba HealthCare: Goodwin Procter (Maxence Bloch, William Robert)<br \/>\nLegal advisor to Management Groupe Bio7 and Ardian: Latham &amp; Watkins (Olivier du Mottay,<br \/>\nLouis Paumier, Marion Lebastard)<br \/>\nFinancial advisor to Management Groupe Bio7 and Ardian: Hottinguer Corporate Finance<br \/>\n(Pierre de Bousingen, Djilali Bou-abdallah, Arthur Gautier)<\/p>\n<p>ABOUT ARDIAN<\/p>\n<p>Ardian is a world-leading private investment house with assets of US$67bn managed or advised in<br \/>\nEurope, North America and Asia. The company is majority-owned by its employees. It keeps<br \/>\nentrepreneurship at its heart and focuses on delivering excellent investment performance to its global<br \/>\ninvestor base.<br \/>\nThrough its commitment to shared outcomes for all stakeholders, Ardian\u2019s activities fuel individual,<br \/>\ncorporate and economic growth around the world.<\/p>\n<p>Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly<br \/>\nglobal network, with more than 490 employees working from 13 offices across Europe (Frankfurt,<br \/>\nJersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), North America (New York, San<br \/>\nFrancisco) and Asia (Beijing, Singapore, Tokyo). It manages funds on behalf of about 700 clients<br \/>\nthrough five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate<br \/>\nand Private Debt.<\/p>\n<p>Follow Ardian on Twitter @Ardian<br \/>\n<a href=\"http:\/\/www.ardian.com\">www.ardian.com<\/a><\/p>\n<p>ABOUT CERBA HEALTHCARE<\/p>\n<p>A European leader in clinical pathology, the group is also involved in three complementary segments:<br \/>\n&#8211; local clinical pathology\u2014mainly in France, Belgium, Luxembourg, Italy, and the United Arab<br \/>\nEmirates, through a network of 300 laboratories, 150 sampling centres, and 50 technical facilities;<br \/>\n&#8211; specialised clinical pathology\u2014through Laboratoire Cerba, its original laboratory, serving more than<br \/>\n50 countries in Europe, Africa, and Asia;<br \/>\n&#8211; central lab testing for clinical trials\u2014essential to the development of new molecules by the<br \/>\npharmaceutical and biotechnology industry\u2014through its subsidiaries set up across the 5 continents.<br \/>\nThe group recently diversified through the creation of Cerba Vet, securing a position on the market of<br \/>\nveterinary clinical pathology and genetics.<br \/>\nCerba HealthCare has over 4,500 employees, including 430 medical pathologists.<br \/>\nIn addition to the biologists and managers of the Group, since April 2017, Cerba HealthCare\u2019s<br \/>\nshareholders include the global private markets investment management firm, Partners Group, acting<br \/>\non behalf of its clients, and the Public Sector Pension Investment Board (PSP Investments), one of<br \/>\nCanada\u2019s largest pension investment managers.<br \/>\n<a href=\"http:\/\/www.cerbahealthcare.com\">www.cerbahealthcare.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, March 26, 2018: Ardian, a world-leading private investment house, and the Management and Shareholders of Groupe Bio7, announced today that they have signed an exclusive agreement for the sale of Groupe Bio7, a French-based specialist in clinical analysis, to Cerba HealthCare, a European leader in clinical pathology. Headed by Fr\u00e9d\u00e9ric Barroux, biologist, shareholder and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":8292,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance\" \/>\n<meta property=\"og:description\" content=\"Paris, March 26, 2018: Ardian, a world-leading private investment house, and the Management and Shareholders of Groupe Bio7, announced today that they have signed an exclusive agreement for the sale of Groupe Bio7, a French-based specialist in clinical analysis, to Cerba HealthCare, a European leader in clinical pathology. Headed by Fr\u00e9d\u00e9ric Barroux, biologist, shareholder and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/\" \/>\n<meta property=\"og:site_name\" content=\"Terra Alliance\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-26T20:04:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T08:58:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1300\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"David Albert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"David Albert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/\"},\"author\":{\"name\":\"David Albert\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/#\\\/schema\\\/person\\\/25afd1694770eced9563e2f8c510ccaa\"},\"headline\":\"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare\",\"datePublished\":\"2018-03-26T20:04:42+00:00\",\"dateModified\":\"2026-05-20T08:58:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/\"},\"wordCount\":848,\"image\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/wp-content\\\/uploads\\\/2018\\\/03\\\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/\",\"url\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/\",\"name\":\"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/wp-content\\\/uploads\\\/2018\\\/03\\\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp\",\"datePublished\":\"2018-03-26T20:04:42+00:00\",\"dateModified\":\"2026-05-20T08:58:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/#\\\/schema\\\/person\\\/25afd1694770eced9563e2f8c510ccaa\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/wp-content\\\/uploads\\\/2018\\\/03\\\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp\",\"contentUrl\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/wp-content\\\/uploads\\\/2018\\\/03\\\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp\",\"width\":1300,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/#website\",\"url\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/\",\"name\":\"Terra Alliance\",\"description\":\"International Corporate Finance Advisory\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/#\\\/schema\\\/person\\\/25afd1694770eced9563e2f8c510ccaa\",\"name\":\"David Albert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g\",\"caption\":\"David Albert\"},\"sameAs\":[\"https:\\\/\\\/terra-alliance.com\\\/staging\"],\"url\":\"https:\\\/\\\/terra-alliance.com\\\/staging\\\/author\\\/gp-access\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/","og_locale":"en_US","og_type":"article","og_title":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance","og_description":"Paris, March 26, 2018: Ardian, a world-leading private investment house, and the Management and Shareholders of Groupe Bio7, announced today that they have signed an exclusive agreement for the sale of Groupe Bio7, a French-based specialist in clinical analysis, to Cerba HealthCare, a European leader in clinical pathology. Headed by Fr\u00e9d\u00e9ric Barroux, biologist, shareholder and [&hellip;]","og_url":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/","og_site_name":"Terra Alliance","article_published_time":"2018-03-26T20:04:42+00:00","article_modified_time":"2026-05-20T08:58:48+00:00","og_image":[{"width":1300,"height":800,"url":"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp","type":"image\/webp"}],"author":"David Albert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"David Albert","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#article","isPartOf":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/"},"author":{"name":"David Albert","@id":"https:\/\/terra-alliance.com\/staging\/#\/schema\/person\/25afd1694770eced9563e2f8c510ccaa"},"headline":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare","datePublished":"2018-03-26T20:04:42+00:00","dateModified":"2026-05-20T08:58:48+00:00","mainEntityOfPage":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/"},"wordCount":848,"image":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/","url":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/","name":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare - Terra Alliance","isPartOf":{"@id":"https:\/\/terra-alliance.com\/staging\/#website"},"primaryImageOfPage":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#primaryimage"},"image":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp","datePublished":"2018-03-26T20:04:42+00:00","dateModified":"2026-05-20T08:58:48+00:00","author":{"@id":"https:\/\/terra-alliance.com\/staging\/#\/schema\/person\/25afd1694770eced9563e2f8c510ccaa"},"breadcrumb":{"@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#primaryimage","url":"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp","contentUrl":"https:\/\/terra-alliance.com\/staging\/wp-content\/uploads\/2018\/03\/Insights-Exclusive-agreement-signed-for-sale-of-Groupe-Bio7-to-Cerba-Healthcare.webp","width":1300,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/terra-alliance.com\/staging\/exclusive-agreement-signed-for-sale-of-groupe-bio7-to-cerba-healthcare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/terra-alliance.com\/staging\/"},{"@type":"ListItem","position":2,"name":"Exclusive agreement signed for sale of Groupe Bio7 to Cerba Healthcare"}]},{"@type":"WebSite","@id":"https:\/\/terra-alliance.com\/staging\/#website","url":"https:\/\/terra-alliance.com\/staging\/","name":"Terra Alliance","description":"International Corporate Finance Advisory","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/terra-alliance.com\/staging\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/terra-alliance.com\/staging\/#\/schema\/person\/25afd1694770eced9563e2f8c510ccaa","name":"David Albert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1529eed45fa537720e95d345b32158e5dddf42c5138705b6f3ebc5167bf7ef93?s=96&d=mm&r=g","caption":"David Albert"},"sameAs":["https:\/\/terra-alliance.com\/staging"],"url":"https:\/\/terra-alliance.com\/staging\/author\/gp-access\/"}]}},"_links":{"self":[{"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/posts\/3741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/comments?post=3741"}],"version-history":[{"count":3,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/posts\/3741\/revisions"}],"predecessor-version":[{"id":8293,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/posts\/3741\/revisions\/8293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/media\/8292"}],"wp:attachment":[{"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/media?parent=3741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/categories?post=3741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/terra-alliance.com\/staging\/wp-json\/wp\/v2\/tags?post=3741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}